Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00562965 · ClinicalTrials.gov registry record · Phase 3
Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 29
- Enrollment target
NCT00562965 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 29 participants.
The verdict
NCT00562965, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 29 participants
- Enrollment target
Study Summary
This protocol is designed to assess the efficacy and safety of inotuzumab ozogamicin given with rituximab compared to a defined investigator's choice therapy. Subjects will be randomized to one of these two arms of the study.
Interventions
- DRUG cyclophosphamide
- DRUG rituximab
- DRUG vincristine
- DRUG inotuzumab ozogamicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2007-11 |
| Est. Completion | 2011-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00562965
The ClinicalTrials.gov registry entry for NCT00562965 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which cyclophosphamide is the first listed.
NCT00562965 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00562965 about?
NCT00562965 is a clinical study titled "Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)". This protocol is designed to assess the efficacy and safety of inotuzumab ozogamicin given with rituximab compared to a defined investigator's choice therapy. Subjects will be randomized to one of these two arms of the study.
What is the current status of trial NCT00562965?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 29 participants. The study started on 2007-11. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00562965?
The interventions under investigation include: cyclophosphamide (DRUG), rituximab (DRUG), vincristine (DRUG), inotuzumab ozogamicin (DRUG).
Who is sponsoring clinical trial NCT00562965?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.